Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $54.19 down -1.45% from its previous closing price of $54.99. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 1.31 million shares were traded. PTGX stock price reached its highest trading level at $55.02 during the session, while it also had its lowest trading level at $51.5528.
Ratios:
For a deeper understanding of Protagonist Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.02. For the most recent quarter (mrq), Quick Ratio is recorded 17.26 and its Current Ratio is at 17.26. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $72.
On December 06, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $62 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 22 ’25 when PATEL DINESH V PH D sold 22,065 shares for $55.05 per share. The transaction valued at 1,214,678 led to the insider holds 548,538 shares of the business.
PATEL DINESH V PH D sold 17,520 shares of PTGX for $959,921 on Jul 23 ’25. The President and CEO now owns 531,018 shares after completing the transaction at $54.79 per share. On Jul 21 ’25, another insider, PATEL DINESH V PH D, who serves as the President and CEO of the company, sold 12,859 shares for $54.86 each. As a result, the insider received 705,445 and left with 570,603 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3358804480 and an Enterprise Value of 2795802112. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.16 while its Price-to-Book (P/B) ratio in mrq is 4.87. Its current Enterprise Value per Revenue stands at 13.454 whereas that against EBITDA is 99.661.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.34, which has changed by 0.30358434 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $32.50. The 50-Day Moving Average of the stock is 5.10%, while the 200-Day Moving Average is calculated to be 19.84%.
Shares Statistics:
For the past three months, PTGX has traded an average of 870.72K shares per day and 706740 over the past ten days. A total of 61.93M shares are outstanding, with a floating share count of 58.35M. Insiders hold about 5.85% of the company’s shares, while institutions hold 102.57% stake in the company. Shares short for PTGX as of 1751241600 were 6731615 with a Short Ratio of 7.73, compared to 1748563200 on 5209196. Therefore, it implies a Short% of Shares Outstanding of 6731615 and a Short% of Float of 13.03.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Protagonist Therapeutics Inc (PTGX) in the stock market is under the watchful eye of 9.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.3 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$0.29 and -$2.52 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$1.17, with 9.0 analysts recommending between $2.75 and -$3.71.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $253.4M, while the lowest revenue estimate was $28.3M, resulting in an average revenue estimate of $81.31M. In the same quarter a year ago, actual revenue was $434.43M
